On the other hand, it is difficult to enhance anti-cancer immune responses and even if immunosuppression is overcome (12) in patients with a low, making it necessary to target not only neoantigens but also shared antigens like glypican (GPC)-3. The gene discussed is GPC3; the disease is cancer.